Alberto Briganti1, Nicola Fossati2, James W F Catto3, Philip Cornford4, Francesco Montorsi2, Nicolas Mottet5, Manfred Wirth6, Hendrik Van Poppel7. 1. Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: briganti.alberto@hsr.it. 2. Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. 3. Academic Urology Unit, University of Sheffield, Sheffield, UK. 4. Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK. 5. Department of Urology, University Hospital, St. Etienne, France. 6. Department of Urology, Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. 7. Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Abstract
Active surveillance (AS) represents a well-recognized management option for many patients with low- and very low-risk prostate cancer (PCa). AS aims to reduce overtreatment whilst ensuring curative treatment for those in whom it is needed, without losing the window of curability. While long-term series have confirmed the safety of AS in carefully selected patients, this has resulted in new clinical questions. Can the inclusion criteria be expanded? Is there a role for biomarkers and multiparametric magnetic resonance imaging at diagnosis or during AS? What is the optimal follow-up schedule as well as the most meaningful trigger for definitive treatment? These questions, together with increasingly adopted heterogeneous protocols in AS, have prompted the European Association of Urology to produce a position paper corroborated by a summary of the scientific background on AS. PATIENT SUMMARY: Active surveillance (AS) is becoming a widely adopted strategy for patients affected by low-risk prostate cancer. While a formal systematic review on the topic will soon be available, the European Association of Urology has produced specific statements for different open questions on AS.
Active surveillance (AS) represents a well-recognized management option for many patients with low- and very low-risk prostate cancer (PCa). AS aims to reduce overtreatment whilst ensuring curative treatment for those in whom it is needed, without losing the window of curability. While long-term series have confirmed the safety of AS in carefully selected patients, this has resulted in new clinical questions. Can the inclusion criteria be expanded? Is there a role for biomarkers and multiparametric magnetic resonance imaging at diagnosis or during AS? What is the optimal follow-up schedule as well as the most meaningful trigger for definitive treatment? These questions, together with increasingly adopted heterogeneous protocols in AS, have prompted the European Association of Urology to produce a position paper corroborated by a summary of the scientific background on AS. PATIENT SUMMARY: Active surveillance (AS) is becoming a widely adopted strategy for patients affected by low-risk prostate cancer. While a formal systematic review on the topic will soon be available, the European Association of Urology has produced specific statements for different open questions on AS.
Authors: Gregory T Chesnut; Emily A Vertosick; Nicole Benfante; Daniel D Sjoberg; Jonathan Fainberg; Taehyoung Lee; James Eastham; Vincent Laudone; Peter Scardino; Karim Touijer; Andrew Vickers; Behfar Ehdaie Journal: Eur Urol Date: 2019-12-23 Impact factor: 20.096
Authors: Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan Journal: Nat Rev Urol Date: 2019-07-17 Impact factor: 14.432
Authors: Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor Journal: Med Decis Making Date: 2019-10-21 Impact factor: 2.583
Authors: Jane M Lange; Aaron A Laviana; David F Penson; Daniel W Lin; Anna Bill-Axelson; Sigrid V Carlsson; Lisa F Newcomb; Bruce J Trock; H Ballentine Carter; Peter R Carroll; Mathew R Cooperberg; Janet E Cowan; Laurence H Klotz; Ruth B Etzioni Journal: Cancer Date: 2019-10-22 Impact factor: 6.860
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Andrew W Silagy; Kyrollis Attalla; Renzo G Dinatale; Kate L Weiss; Stanley Weng; Roy Mano; Skylar Iosepovici; Julian Marcon; Ed Reznik; Ritesh R Kotecha; Robert J Motzer; Martin H Voss; Jonathan A Coleman; A Ari Hakimi; Paul Russo Journal: World J Urol Date: 2021-03-29 Impact factor: 3.661
Authors: Justin R Gregg; John W Davis; Chad Reichard; Xuemei Wang; Mary Achim; Brian F Chapin; Louis Pisters; Curtis Pettaway; John F Ward; Seungtaek Choi; Quynh-Nhu Nguyen; Deborah Kuban; Richard Babaian; Patricia Troncoso; Lydia T Madsen; Christopher Logothetis; Jeri Kim Journal: Urology Date: 2019-12-30 Impact factor: 2.649
Authors: Bas Israël; Jos Immerzeel; Marloes van der Leest; Gerjon Hannink; Patrik Zámecnik; Joyce Bomers; Ivo G Schoots; Jean-Paul van Basten; Frans Debruyne; Inge van Oort; Michiel Sedelaar; Jelle Barentsz Journal: BJU Int Date: 2021-08-23 Impact factor: 5.969